Ontario and Quebec provide reimbursement for HIV therapies Pifeltro (doravirine) and Delstrigo (doravirine/lamivudine/tenofovir disoproxil fumarate)

18 November 2019 - For more than 30 years, Merck has been committed to scientific research and discovery in HIV that ...

Read more →

Patients in Quebec now have access to Dupixent for the treatment of moderate-to-severe atopic dermatitis

22 October 2019 - Quebec becomes the first province to list Dupixent for public reimbursement in adult patients. ...

Read more →

Novartis completes certification of initial sites in Quebec for first approved Canadian CAR-T therapy, Kymriah (tisagenlecleucel)

9 October 2019 - Quebec government to reimburse Kymriah therapy for certain patients with life-threatening cancers who are in critical ...

Read more →

Addition of Kisqali to drug plan in Quebec expands access to treatment for metastatic breast cancer

19 September 2019 - Provincial reimbursement provides public access to treatment that may delay the progression of advanced breast cancer. ...

Read more →

Quebec becomes first province to list Lonsurf (trifluridine/tipiracil) for public reimbursement for adult patients with metastatic colorectal cancer

19 August 2019 - Cancer treatment taken orally shown to extend overall survival in patients whose disease has progressed following treatment ...

Read more →

Could Quebec’s public drug plan work for national pharmacare?

30 July 2019 - Quebec’s universal pharmacare program offers better drug coverage and quicker approval for new drugs coming to ...

Read more →

Quebec’s public-private pharmacare model provides more generous—and timely—access to new drugs

25 July 2019 - Quebec’s universal pharmacare system, which relies on both a public plan and private insurance providers, covers ...

Read more →

Quebec appeals court orders province to restore full coverage of rheumatoid-arthritis drug Remicade

13 February 2019 - Quebec’s highest court has ordered the provincial government to restore full public coverage of Remicade, an ...

Read more →

Quebec and New Brunswick become first provinces to provide public funding of Ibrance for the first-line treatment of metastatic breast cancer

15 February 2018 - Since Ibrance received Health Canada marketing authorisation in March 2016, Canadian women living with metastatic breast cancer ...

Read more →